BioSpace News Archive

The hospital, which serves communities in and around Monticello, purchased the DRX-Excel Plus to provide easy access to a suite of imaging services.

Danaher Corporation announced that its wholly owned subsidiary, DH Europe Finance II S.à r.l., has priced an offering

Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA) and Kedrion Biopharma two leading plasma-derived protein therapeutics companies, announced today that the results of their registration study for KEDRAB® [Rabies Immune Globulin (Human)] were published in Human Vaccines & Immunotherapeutics, a peer-reviewed medical journal covering research into vaccines and immunotherapeutics in humans.

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced the Company will release its financial results for the third quarter ended September 30, 2019, before the market opens on Tuesday, November 12, 2019.

Ceapro Inc. announced that the European and U.S. Patent and Trademark Offices have issued the Company European Patent No. 2411527 and U.S. Patent No. 10,334,869 entitled, “Method For Increasing Concentration of Avenanthramides in Oats,” related to the production of its value-driver product, avenanthramides, utilizing a malting technology in-licensed from Agriculture and Agri-Food Canada.

Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, announced the appointment of Richard Morris as chief financial officer.

Chimerix, Inc. announced that it will host a live conference call and audio webcast on Tuesday, November 5, 2019 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2019, and to provide an operational update..

Tabula Rasa HealthCare, Inc., a healthcare technology company advancing the field of medication safety, began services with Silver Star PACE on October, 2019 through its CareVention HealthCare™ Division.

Company Enters Into Common Stock Purchase Agreement with Vivozon, Inc.

Safety data from all patients (Phase 1 and Phase 2) show that B-VEC was well tolerated with no related adverse events reported.